Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis

Ann Rheum Dis. 2022 Feb;81(2):296-299. doi: 10.1136/annrheumdis-2021-221093. Epub 2021 Sep 11.

Authors

Ichiro Yoshii¹, Naoya Sawada², Tatsumi Chijiwa³, Shohei Kokei⁴

Affiliations

¹ Musculoskeletal Medicine, Yoshii Hospital, Shimanto-City, Kochi, Japan [email protected].
² Department of Rheumatology, Dohgo-Onsen Hospital Rheumatology Center, Matsuyama, Ehime, Japan.
³ Department of Rheumatology, Kochi Memorial Hospital, Kochi, Kochi, Japan.
⁴ Department of Internal Medicine, Yoshii Hospital, Shimanto-City, Kochi, Japan.

PMID: 34509991
DOI: 10.1136/annrheumdis-2021-221093

No abstract available

Keywords: disease activity; osteoporosis; rheumatoid arthritis.

Publication types

Letter

MeSH terms

Aged
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / complications*
Arthritis, Rheumatoid / drug therapy
Female
Humans
Incidence
Male
Middle Aged
Osteoporotic Fractures / epidemiology*
Patient Acuity
Remission Induction
Risk Factors

Substances

Antirheumatic Agents